Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

Overview of attention for article published in Journal of Clinical Oncology, March 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 5 public wall posts from 4 users.

As first-line therapy for HER2-positive metastatic BC, lapatinib combined with taxane was associated with shorter PFS and more…

First-line therapy for HER2-positive metastatic breast cancer: Lapatinib vs trastuzumab w/taxane therapy http://bit.ly/1Lqu6ac

HER2陽性転移性乳がん初回治療では、trastuzumab+taxaneと比較してlapatinib+taxaneはprogression-free survivalが短く、毒性が強い (文献2015-071)。 "Lapatinib or…

As first-line therapy for HER2-positive metastatic breast cancer, lapatinib combined with taxane was associated with shorter…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity, including 1 additional Facebook posts.